All News
#ACRbest Abstracts – Day 3
Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)
Read Article
Clinical Year in Review at #ACR23
By @philseo (@jhrheumatology)
Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
Mithu Maheswaranathan, MD ( View Tweet)
My takeaways from #ACR23 #ReviewCourse session on Inflammatory Eye Disease - Dr. Laura Kopplin:
1. Systemic therapy has better long term outcomes than topical treatments, but many/most ophthalmologists are uncomfortable with prescribing there.
2. FAST Trial: Methotrexate better… https://t.co/eoSeWVHsf0
Paul Sufka, MD psufka ( View Tweet)
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/TnCsgxOfCM https://t.co/HEd4NWnuuX
Dr. John Cush RheumNow ( View Tweet)
Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype..
#Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4
dX.Martínez ( View Tweet)
Latest in Lupus Treatment at #ACR23
• Dr. Dall’Era & Dr. Furie
• Approach to Lupus Nephritis 🫘
• Treating Non-Renal SLE / Skin
#Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe
Mithu Maheswaranathan, MD ( View Tweet)
Great time at the Knowledge Bowl! Huge thanks to my co-hosts, judges, and amazing #ACR23 staff
Congrats to the IGGenerals for taking home the big prize and kudos to ANA 1:40 for the much deserved spirit award! https://t.co/u7bFeQjXeY
Mike Putman EBRheum ( View Tweet)
ARTIC REWIND RCT 3 yrs csDMARD withdrawal
38% 3yrs csDMARDs free remission vs. 80% stable dose gpe
75% recovery after restart
Rx progression 19% in half dose gpe
More use bioDMARDs (18%) & GCs (50%) withdraw gpe
Trends towards lower infections
@RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS
Aurelie Najm ( View Tweet)
Low dose #prednisone has (bad) brain effects. An argument to use steroid sparing drugs in #PMR @philseo @ACRheum @RheumNow #ACR23 THINK about steroid sparing Rx in ?all pts with #PMR #Great #debate https://t.co/usQJRNUN8B
Janet Pope ( View Tweet)
Anterior uveitis incidence across different axSpA treatments
Large review and meta-analysis on TNFi, IL-17i, JAKi
Immunomodulatory therapy protective against uveitis flare
Greatest in TNFi and JAKi
@RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt
Robert B Chao, MD ( View Tweet)
#Lupus #ACR23🦋
🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy
🔥Promising step towards future in revolutionizing Lupus T/t💡📑
💡Keeps efficacy of other vaccines intact!
Follow this thread showcasing other imp findings
#ACRambassador
1/2 https://t.co/aNFTmJiH0X
debaditya_roy ( View Tweet)
✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus:
BEFORE stepping-up with biologics, ask the key questions:
-Are you using proton-pump inhibitors (Drug-induced SCLE)
-Can I see your sunscreen?
-Can I see your hat?
-Are you smoking?
-Any HCQ blood levels? https://t.co/s73FqyjLOn
Laurent ARNAUD ( View Tweet)
#CAR T cells #ACR23
🔥Back to back Sessions on one of the most avidly researched area in Rheum!
💡Check out these slides to understand:
☣️Toxicities and Limitations of CAR T therapy
🆕 Novel CAR designs
⚡️CAR cell sources
❓Research Questions to ponder!
#ACRambassador https://t.co/6sOn4rjqY3
debaditya_roy ( View Tweet)
Toxicities and limitations of CAR therapy:
the other side of its incredibly exciting, boundless potential
@Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC
David Liew drdavidliew ( View Tweet)
Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor.
46% flared
Seropositive- OR 2.0
NO association with mortality
-ICIs are safe to use in RA
-Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Conundrum of #Clinically #Quiescent #Serologically #Active #SLE-half flare within 5 yrs; can have organ damage. Large cohort-China
20% met def’n- diff trajectories
37% flare
1/6 got damage in f/u
Some tapered Rx
How to identify safe to d/c Rx?
2555 #ACR23 @ACRheum @RheumNow https://t.co/f49BQspQsz
Janet Pope ( View Tweet)
Are all ICI-IA irAEs the same?
@cappelliMD @jhrheumatology presented lovely work: latent class analysis on her cohort data
She found two phenotypes - one with more persistent symptoms, & potentially a start in stratifying irAE therapy going forward.
#ACR23 ABST2513 @RheumNow https://t.co/roW00KwbVZ
David Liew drdavidliew ( View Tweet)
Patella tendon characteristics with USG - thickness, cross sectional area and stiffness measures with shear wave elastography
In pts with or without knee pain
@rheumnow #ACR23 52 pts Pain didnt correralate with thick ess and cross sectional area but did correlate with stiffness https://t.co/q3ZPG1l2n2
Bella Mehta bella_mehta ( View Tweet)
Plenary Abs #2425: Pregnancies among vasculitis pts - higher frequency of spontaneous abortion and preterm delivery. Risk of maternal complications associated with vasculitis were observed to vary by vessel size and parity. #ACR23 https://t.co/qLcpNapcjg @rheumnow https://t.co/sk3dhySVfP
Dr. Rachel Tate ( View Tweet)